Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Basic Materials
  3. OTC
  4. RDSMY

Market Cap: $0

KN

Koninklijke DSM N.V.

RDSMY
OTC (Other OTC)USD
Invest in RDSMY
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

–
–(–)

Open

$33.22

Prev. Close

$32.77

High

$33.90

Low

$33.11

Key Statistics

52-Week Range24% of range
Low $26.59High $56.92
Market Cap
$0
P/E Ratio
7.04x
EPS (TTM)
$4.33

More on Koninklijke DSM N.V.

  • News & announcements
  • Financials

Koninklijke DSM N.V. at a Glance

  • Pre-revenue chemicals - specialty company. Losses are normal at this stage, so cash, debt and dilution matter more than profit.
Dividend Yield
None
Price / Book
0.56x
Beta
0.79
Avg. Volume
255.05K

Company Profile

Koninklijke DSM N.V. is a science-driven enterprise, headquartered in Heerlen, the Netherlands, and founded in 1902, that develops and delivers solutions for nutrition, health, and sustainable living globally. Its operations extend across the Netherlands, Switzerland, the rest of Europe, North and Latin America, China, other parts of Asia, and international markets. The company's activities are structured across its Nutrition, Materials, and Innovation Center segments. The Nutrition segment provides a comprehensive range of products for both animal and human well-being. For animal nutrition and health, it offers essential items such as vitamins, premixes, carotenoids, enzymes, microbes, and eubiotics. Within human nutrition and health, its portfolio includes vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics, prebiotics, and active pharmaceutical ingredients. This segment also encompasses market-ready and personalized nutrition solutions, human milk oligosaccharides, ingredients for skin, sun, hair care, and aromas, omega-3 fatty acids, along with specialized food enzymes, cultures, bio-preservation technologies, texturizing hydrocolloids, and savory taste and sugar reduction solutions. The Materials segment specializes in high-performance plastics crucial for manufacturing components in diverse industries like electrical and electronics, automotive, flexible food-packaging, and consumer goods. It also produces Dyneema, a unique fiber solution integral to personal protection, workwear, sports apparel, outdoor equipment, and various industrial applications including ropes, slings, synthetic chains, and nets for aquaculture and renewable energy sectors. Finally, the Innovation Center segment focuses on advancing biomedical materials and medical device manufacturing technologies. Its applications span critical areas such as cardiovascular, continence care, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, peripheral vascular, plastic and reconstructive surgery, and wound management. Additionally, this segment is responsible for commercializing yeast technology used in ethanol production.

CEODimitri de Vreeze
SectorBasic Materials
IndustryChemicals - Specialty
Employees21.8K
IPO DateJul 16, 2001
ExchangeOTC
Exchange NameOther OTC
CurrencyUSD
Headquarters & Contact
AddressHet Overloon 1
City / State / ZIPHeerlen, 6411 TE
CountryNetherlands
Phone

RDSMY Stock FAQ

What does Koninklijke DSM N.V. do?

Koninklijke DSM N.V.

Where is Koninklijke DSM N.V. stock listed?

Koninklijke DSM N.V. trades on the Other OTC under the ticker RDSMY, priced in USD.

What is RDSMY's 52-week high and low?

Over the past 52 weeks RDSMY has traded between $26.59 and $56.92.

Does Koninklijke DSM N.V. pay a dividend?

No. Koninklijke DSM N.V. does not currently pay a dividend.

Is Koninklijke DSM N.V. profitable?

Not yet. Koninklijke DSM N.V. is an exploration-stage company, so losses are expected while it develops its projects. Already generating positive free cash flow despite being early stage.

What do analysts think of RDSMY stock?

The analyst consensus rating for RDSMY is Buy.

Who is the CEO of Koninklijke DSM N.V.?

Dimitri de Vreeze is the CEO of Koninklijke DSM N.V., which is headquartered in Heerlen.

Already generating positive free cash flow despite being early stage.
  • Positive working capital of $3.7B (current assets minus current liabilities).
  • Moderate debt: borrowings are 0.33x shareholders' equity.
  • Shares trade below book value (price-to-book 0.56x).
  • Analyst consensus rating: Buy.
  • Generated automatically from reported financial data. General information only, not financial advice.

    Fundamentals Scorecard

    Each pillar is scored out of 5 from the latest reported data.

    Not enough reported data to score yet

    Scores need financial statements filed by the company. This is common for recently listed and early-stage companies.

    See the full financial breakdown →
    31 45 578 8111
    Websitehttps://www.dsm.com